Article Text

PDF
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
  1. F H M Prince1,
  2. M Twilt1,2,
  3. R ten Cate2,
  4. M A J van Rossum3,4,
  5. W Armbrust5,
  6. E P A H Hoppenreijs6,
  7. M van Santen-Hoeufft7,
  8. Y Koopman-Keemink8,
  9. N M Wulffraat9,
  10. L W A van Suijlekom-Smit1
  1. 1
    Department of Paediatrics/Paediatric Rheumatology, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands
  2. 2
    Department of Paediatrics/Paediatric Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  3. 3
    Department of Paediatrics/Paediatric Rheumatology, Emma Children’s Hospital AMC, Amsterdam, The Netherlands
  4. 4
    Jan van Breemen Institute, Amsterdam, The Netherlands
  5. 5
    Department of Paediatrics/Paediatric Rheumatology, Beatrix Children’s Hospital, University Medical Centre Groningen, Groningen, The Netherlands
  6. 6
    Department of Paediatrics/Paediatric Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  7. 7
    Department of Internal Medicine, Subdivision of Rheumatology, Academic Hospital Maastricht, Maastricht, The Netherlands
  8. 8
    Department of Paediatrics/Paediatric Rheumatology, Hagaziekenhuis Juliana Children’s Hospital, Den Haag, The Netherlands
  9. 9
    Department of Paediatrics/Paediatric Rheumatology, Utrecht MC Wilhelmina Children’s Hospital, Utrecht, The Netherlands
  1. F H M Prince, Department of Paediatrics, Sp 1545, Erasmus MC Sophia Children’s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands; f.prince{at}erasmusmc.nl

Abstract

Objective: We undertook an observational study to obtain a complete overview of the long-term effectiveness and safety of etanercept in patients with different juvenile idiopathic arthritis (JIA) subtypes.

Methods: At baseline we collected patient and disease characteristics of all Dutch patients with JIA who started treatment with etanercept. Disease activity was evaluated (at start of the study, after 3 months and then yearly) according to the JIA core set of the American College of Rheumatology paediatric definition for 30, 50 and 70% improvement (ACR Pedi 30, 50 and 70). Use of etanercept and concomitant drugs was monitored. Adverse events were recorded.

Results: We included 146 patients with JIA with a median follow-up of 2.5 years per patient (range 0.3–7.3). JIA subtypes represented: 27% systemic, 8% polyarticular rheumatoid factor positive, 38% polyarticular rheumatoid factor negative, 19% oligoarticular extended, 3% enthesitis-related and 5% psoriatica. Most patients (77%) met the criteria of the ACR Pedi 30 in the first 3 months of treatment. For the majority of patients this improvement was sustained; 53 (36%) of all patients met the remission criteria. No other second-line agents were needed in 43 patients. Although patients with systemic JIA responded initially less to etanercept therapy than patients from other subtypes, those who did respond showed equal effectiveness in the long term. Serious adverse events rate was low (0.029 per patient year).

Conclusions: Etanercept is effective and safe in JIA, even for a large proportion of the patients with systemic JIA. The greatest improvement occurred in the first 3 months of treatment, and was sustained for a long time in most patients (up to 75 months).

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Ethics approval: The protocol was approved by the Medical Ethical Committee of Erasmus MC, Rotterdam. Written informed consent was obtained, and the study was conducted in accordance with the Declaration of Helsinki.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.